BI-6C9 is a synthetic small molecule belonging to the class of thiazolyl-benzimidazole derivatives that acts as a potent inhibitor of the protein kinase CK2. By binding to the catalytic subunit of CK2,… Read more
BI-6C9 is a synthetic small molecule belonging to the class of thiazolyl-benzimidazole derivatives that acts as a potent inhibitor of the protein kinase CK2. By binding to the catalytic subunit of CK2, this compound effectively blocks enzyme activity, positioning it as a therapeutic candidate for cancers driven by CK2 overexpression. Pharmaceutical laboratories utilize BI-6C9 reference standards to support rigorous drug development processes, including method validation and impurity profiling. Our catalogue of BI-6C9 metabolites and stable isotope labelled compounds provides the essential analytical tools needed for accurate identification and quantification during high-resolution mass spectrometry studies. These high-quality reference materials are critical for researchers conducting stability testing, metabolic pathway elucidation, and quality control assessments to ensure the consistency and safety of pharmaceutical formulations throughout the clinical development lifecycle.